Why the study?
Influenza viral ribonucleoprotein complexes play a key role in viral transcription and replication, prompting interest in developing novel anti-influenza drugs targeting them.
Targeting viral ribonucleoprotein complexes (vRNPs) represents a promising strategy for developing new antiviral therapies against influenza.
vRNP-targeted agents may expand influenza options; leaves open need for clinical efficacy trials.
INTRODUCTION: Influenza viral ribonucleoprotein complexes (vRNPs) play a key role in viral transcription and replication; hence, the recent development of novel anti-influenza drugs targeting vRNPs has garnered widespread interest. AREAS COVERED: We discuss the function of the constituents of vRNPs and summarize those vRNPs-targeted synthetic drugs that are in preclinical and early clinical development. EXPERT OPINION: vRNPs contain high-value drug targets; such targets include the subunits PA, PB1, PB2, and NP. Developing a new generation of antiviral therapies with strategies that utilize existing drugs, natural compounds originated from new resources and novel drug combinations may open up new therapeutic approaches to influenza.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: